406 filings
Page 2 of 21
8-K
7w7nuu
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
iz50la
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
8-K
75zo4h871vpx
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
D
g3ccia2r8i4
20 Oct 23
$2.89 mm in options / securities to be acquired, 1 investor
1:04pm
8-K
ko5qm2yqc36nc2
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
35vo kfa0
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
sok4dbjpixio4lw
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
38b7l7h5lms1juvr7g
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
lcqzeoa0
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
tmn9rcx5rvj7esiv6
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
a6c gbkjne08300
16 Aug 23
Other Events
4:00pm
8-K
lkzfuk
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
gilhc0if4w7vq vgr
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
a5f7izu94zuzx
21 Jul 23
Entry into a Material Definitive Agreement
5:00pm
8-K
6apy54hus ex0uyzo
3 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:31am
8-K
vrqz4 8d10
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
ruvkahw
28 Jun 23
Departure of Directors or Certain Officers
7:00am